Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease
O Gutierrez, T Isakova, E Rhee, A Shah… - Journal of the …, 2005 - journals.lww.com
Hyperphosphatemia, calcitriol deficiency, and secondary hyperparathyroidism (SHPT) are
common complications of chronic kidney disease (CKD). Fibroblast growth factor-23 (FGF-
23) is a novel phosphaturic hormone that also inhibits renal 1α-hydroxylase activity and thus
may be involved in the pathogenesis of SHPT. Several hypotheses were tested: that FGF-23
increases as renal function declines; is linearly associated with serum phosphate levels; is
associated with increased phosphaturia independent of parathyroid hormone (PTH); and is …
common complications of chronic kidney disease (CKD). Fibroblast growth factor-23 (FGF-
23) is a novel phosphaturic hormone that also inhibits renal 1α-hydroxylase activity and thus
may be involved in the pathogenesis of SHPT. Several hypotheses were tested: that FGF-23
increases as renal function declines; is linearly associated with serum phosphate levels; is
associated with increased phosphaturia independent of parathyroid hormone (PTH); and is …